Cohance Lifesciences Ltd · NSE:COHANCE
Cohance Lifesciences — Q1 FY2027 Earnings Presentation
36 slides from Cohance Lifesciences's earnings presentation, Aug 5, 2026
Slide 1: Cover letter to stock exchanges
5 August 2026 To To BSE Limited National Stock Exchange of India Limited 25th Floor, P. J. Towers, Exchange Plaza, Bandra Kurla Complex Dalal Street, Mumbai - 400001 Bandra (E), Mumbai – 400051 Scrip Code: 543064 Scrip Symbol: COHANCE Dear Sir/Madam, Sub: Investor Presentation Please find annexed in
Slide 2: Investor Presentation Q1 FY2027
Cohance INVESTOR PRESENTATION Q1 FY2027 5t AUGUST 2026
Slide 3: Disclaimer
This document and information herein is solely for information purposes and must not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. This document may not be altered in any way, transmitted to, copied or d
Slide 4: Agenda
Awards & Recognition Executive summary and ESG 04 16 Business and Financial Business wise Strategy performance 06 20 Enhancing stake in sapala Annexure organics 13 31 3
Slide 5: Executive Summary
Cohance EXECUTIVE SUMMARY
Slide 6: Q1 FY27: Performance in line with commentary
Q1 FY27: PERFORMANCE IN LINE WITH COMMENTARY As guided, Q1 was weak on revenue and EBITDA, reflecting shipment and order phasing, an unfavourable product mix, negative operating leverage and subsidiary consolidation. The standalone business remained strong and the balance sheet net-cash positive
Slide 7: Business and Financial Performance
BUSINESS AND FINANCIAL PERFORMANCE 6
Slide 8: Q1 FY27 Financial Highlights
Q1 FY27 performance: Q1 FY27 Financial Highlights Q1 FY27 revenues stood at INR 4,223 Mn, a decline of 23.1% YoY. This was on the back of shipment phasing in Pharma CDMO, a softer contribution from Agrochemicals, lower Formulations revenue and the timing of execution across parts (23.1%) (10.4%) 2
Slide 9: Consolidated Financials Q1 FY26 vs Q1 FY27
INR Mn Particulars Q1FY26 Q1FY27 YoY Revenue from Operations 5,493 4,223 -23.1% • In Q1, CDMO (Pharma CDMO + Specialty Chemicals) share Material costs / COGS (1,481) (1,203) was 38%, all the business segments witnessed revenue Material Margin 4,012 3,020 -24.7% decline. Niche tech stood at 15.1% Mat
Slide 10: Standalone Financials Q1 FY26 vs Q1 FY27
INR Mn Particulars Q1FY26 Q1FY27 YoY Revenue from Operations 4,836 3,599 -25.6% • Standalone gross margins contracted by 50 bps YoY Material costs / COGS (1,460) (1,106) reflecting the product mix primarily led by higher raw Material Margin 3,376 2,493 -26.1% material cost offset by higher realisati
Slide 11: Consolidated Financials
Consolidated Financials Operational Revenue (INR Mn) Adjusted EBITDA (INR Mn) Margin (%) Adjusted PAT (INR Mn) 24.4% 5,493 Q1FY26 Q1FY27 4,223 592 1,341 2.2% 92 (430) Q1FY26 Q1FY27 Q1FY26 Q1FY27 Q1FY26 Q1FY27 Pharma CDMO (INR Mn) Spec Chem (INR Mn) API + (INR Mn) 2,035 505 2,953 2,645 330 1,248 Q1FY
Slide 12: Balance Sheet Snapshot
INR Mn Balance Sheet Snapshot1 FY25 FY26 Q1 FY27 Property, plant and equipment (PPE) 15,583 17,907 17,655 Right of use asset (RoU) 2,418 2,311 2,224 • The balance sheet remains resilient and net cash positive as on Capital work-in-progress 3,316 1,732 1,963 30 June 2026, despite integration and capa
Slide 13: Key Ratios (Adjusted)
Key Ratios(Adjusted)# FY25 FY26 Q1 FY27 Basis Net Working Capital (as days of sales) 136 154 141 NWC / Revenue * 365 days PPE (as % of sales) 57.2% 81.7% 79.5% PPE / Revenue Capex spend during the year/period (INR Mn) 3,147 2,154 598 Capex spend (as % of sales) 12.1% 9.5% 14.2% Capex spend / Revenue
Slide 14: Enhancing Stake in Sapala Organics
ENHANCING STAKE IN SAPALA ORGANICS 13
Slide 15: Sapala Organics overview and 2024 acquisition
Sapala Organics, founded by Dr. P. Y. Reddy, is focused on nucleic acid chemistry, namely oligonucleotide building blocks, mRNA compounds) o The Sapala Organics team that possesses over a century of combined experience across 18 labs, began as a trusted partner for Japan’s pharma industry o It hol
Slide 16: Bringing together chemistry, development, manufacturing and commercial supply
Customer feedback indicates that they would prefer to engage with Cohance through a more end- to-end integrated nucleic-acid offering—bringing together chemistry, development, manufacturing and commercial supply rather than just a supplier of individual nucleic-acid building blocks Cohance proposes
Slide 17: Awards & Recognition and ESG
AWARDS & RECOGNITION AND ESG 16
Slide 18: Awards, ratings and SBTi validation
Independent recognition of Cohance's Science-Based Targets: SBTi Validation safety culture and sustainability Near-term and net-zero emissions targets formally performance validated by SBTi Services EcoVadis Gold Rating and CDP rating NEAR-TERM — FY2035 Cohance's sustainability assessment score prog
Slide 19: Projects Status: Renewable Energy
Projects Status: Renewable Energy Solar Group Captive implementation and usage of green fuels — advancing our path to Net-Zero by 2050 ROADMAP OPERATIONAL COMPLETED 7 MWp solar plant commissioned at Ankleshwar under the 7 MWp Solar Power Plant Group Captive model and around 3 MWp solar panels are An
Slide 20: ESG Profile
We have set multi-dimensional ESG goals Our achievement Environment Social Governance Up coming milestones Achieved B rating in Climate Retention of Eco Vadis Gold Change and A- Water in 2025 Reduce absolute Scope 1,2 Employees undergo Ethical non- in Sustainability assessment 58+% and 3 emissions f
Slide 21: Business Wise Strategy
BUSINESS WISE STRATEGY 20
Slide 22: Business strategy by segment
39% Specialty 13% 48% Pharma CDMO* API+* of Sales Chemicals* of Sales of Sales Small Molecules ADC* Payload –linker – Thrust on adding anchor relationships and Expanding selectively into adjacent, 18 Commercial Patented Bioconjugation identifying new growth drivers higher-value opportunities a
Slide 23: Pharma CDMO
Cohance PHARMA CDMO
Slide 24: Customer centricity and strengthening technology modalities
Our 30+ year relationships with global innovators and proven expertise in scaling up hazardous chemistry, complex chiral and multi step synthesis offer us a significant and unique advantage. Customer Centricity and Readiness: o Customer at the core of all initiatives — delivering reliability, spee
Slide 25: Small Molecules
Small Molecules Quality of the portfolio remains strong, with commercial sales continuing to contribute ~57% of the Phase III pipeline standalone business, providing a stable base of repeat and late-lifecycle revenues Phase III molecules Phase III intermediate Q1 was affected by customer shipmen
Slide 26: ADC and Oligonucleotides
ADC Completion of RFP inflows GMP Near-term showing good bioconjugation One new ADC USD 10m US- demand traction post batches and payload DMF based cGMP influenced by recent DMF delivery of an filed; three expansion biotech funding filings for newer end-to-end ADC additional underway, cycles, though
Slide 27: ADC platforms, NJ Bio and Sapala
ADC Payloads and Linkers — India Platform The India-based ADC business continues to expand its capabilities across customised payloads, linkers and highly potent intermediates Three payload-related Drug Master Files were filed during FY26. Customer engagement is progressing across established pa
Slide 28: API+
Cohance API+
Slide 29: API+ outlook
API+ continues to benefit from leadership in niche APIs, cost competitiveness, backward integration and a diversified customer base Purchase order received for the commercial product previously affected by destocking provides improved revenue visibility for FY27 The business is expected to pro
Slide 30: Specialty Chemicals
Cohance SPECIALTY CHEMICALS
Slide 31: Specialty Chemicals: AgChem and Performance Chemicals
Specialty Chemicals — AgChem AgChem has started Additional FY27 will primarily be A key active- FY27 broadly in line programmes with a year of customer ingredient with plan customers in Japan, qualification and programme is Commercial Europe and the manufacturing expected to become production for an
Slide 32: Annexures
ANNEXURES 31
Slide 33: Organisation structure
Executive Chairman Expanded and and CEO All CXO positions in strengthened SHARED place Business SERVICES Development, Quality & R&D functions BUSINESS PARTNERS CDMO API+ SpecChem QUALITY Most new hires from leading Operations Operations Operations Indian pharma SCM companies R&D function R&D R&D R&D
Slide 34: Manufacturing sites and facilities
Lab & Kilo scale Pilot and Commercial scale (~3,000+ kL capacity) Pharma CDMO Genome valley, Nacharam, Hyderabad Princeton, Suryapet, Pashamylaram, Vizag, Nacharam, Jeedimetla, Hyderabad Hyderabad (Oligo CoE) New Jersey Telangana Hyderabad Andhra Pradesh Hyderabad API+ Atchutapuram, Jaggaiahpet, Ank
Slide 35: Investor relations contacts
Cyndrella Carvalho, Head - Investor Relations Cohance Lifesciences Ltd Email: cyndrella.carvalho@cohance.com Gavin Desa, Konpal Pali CDR - India Tel: +91 98206 37649; +91 76619 08341 Email: gavin@cdr-india.com; konpal@cdr-india.com 34
Slide 36: Thank You
Conhance THANK YOU
Cohance Lifesciences — Q1 FY2027 Earnings Presentation on 6ix